Rhythm Pharmaceuticals (RYTM) Consolidated Net Income (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) reported Consolidated Net Income of -$55.6 million for Q1 2026, down 12.36% year-over-year from -$63.5 million in Q1 2025, and down 17.12% quarter-over-quarter from -$47.5 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Consolidated Net Income (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 11 years of Consolidated Net Income data on file, last reported at -$55.6 million in Q1 2026.
- Consolidated Net Income for Q1 2026 came in at -$55.6 million, down 12.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$202.6 million (down 20.05% YoY), and the FY2025 annual result was -$196.5 million, up 24.58% from the prior year.
- Consolidated Net Income slipped to -$55.6 million in Q1 2026 per RYTM's latest filing, from -$47.5 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$32.3 million in Q2 2024 and troughed at -$141.4 million in Q1 2024.
- A 5-year average of -$51.7 million and a median of -$46.6 million in 2025 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income tumbled 220.07% in 2022, then jumped 64.97% in 2025.
- A 5-year view of Consolidated Net Income shows it stood at -$42.5 million in 2022, then increased by 2.02% to -$41.6 million in 2023, then slipped by 4.07% to -$43.3 million in 2024, then dropped by 9.64% to -$47.5 million in 2025, then declined by 17.12% to -$55.6 million in 2026.
- Business Quant data shows RYTM's Consolidated Net Income at -$55.6 million in Q1 2026, -$47.5 million in Q4 2025, and -$52.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Rhythm Pharmaceuticals | 6.59 Bn | 6.25 Bn | 52.96 Mn | -55.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.64 Mn |
| Dec 31, 2025 | -47.51 Mn |
| Sep 30, 2025 | -52.90 Mn |
| Jun 30, 2025 | -46.60 Mn |
| Mar 31, 2025 | -49.52 Mn |
| Dec 31, 2024 | -43.33 Mn |
| Sep 30, 2024 | -43.69 Mn |
| Jun 30, 2024 | -32.26 Mn |
| Mar 31, 2024 | -141.37 Mn |
| Dec 31, 2023 | -41.63 Mn |
| Sep 30, 2023 | -44.16 Mn |
| Jun 30, 2023 | -46.70 Mn |
| Mar 31, 2023 | -52.18 Mn |
| Dec 31, 2022 | -42.49 Mn |
| Sep 30, 2022 | -40.86 Mn |
| Jun 30, 2022 | -44.87 Mn |
| Mar 31, 2022 | -52.53 Mn |
| Dec 31, 2021 | -50.86 Mn |
| Sep 30, 2021 | -35.11 Mn |
| Jun 30, 2021 | -35.39 Mn |